European Organisation for Research and Treatment of Cancer

Tweet this page
Registration as it was on 02 May 2024
How to read and use this data card.
Download this datacard


Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.

Lobbying Costs

None declared

Financial year: Jan 2022 - Dec 2022

Lobbyists (Full time equivalent)

0.45 Fte (3)

Lobbyists with EP accreditation


High-level Commission meetings


Lobbying Costs over the years

  • Info

    European Organisation for Research and Treatment of Cancer   (EORTC)

    EU Transparency Register

    70539554035-46 First registered on 20 Aug 2010

    Goals / Remit

    The European Organisation for Research and Treatment of Cancer (EORTC) has delivered investigator driven, changing practice clinical trials since 1962. Its mission is to improve survival and quality of life of cancer patients. The EORTC is a not-for-profit independent organisation performing multidisciplinary clinical research activities across tumor types. The EORTC aims to improve the standard of cancer treatment through the testing of more effective therapeutic strategies based on drugs, surgery and/or radiotherapy that are already in use. EORTC’s activities involve on a voluntary basis more than 3000 medical doctors and scientists from some 800 university hospitals in 35 countries. EORTC clinical trials are involving several thousands of cancer patients on a yearly basis. The EORTC operates on an independent basis, and in this capacity is able to work in partnership with the pharmaceutical industry in evaluating innovative molecules.

    Main EU files targeted

    - Regulation on clinical trials on medicinal products for human use.
    - Regulation on Health Technology Assessment.
    - Early access to medicines: PRIME, accelerated assessment, conditional market authorization.
    - Good Clinical Practice implementation.
    - General Data Protection Regulation.
    - Regulation of the European Parliament and of the Council on in vitro diagnostic medical devices.
    - Medical Device Regulation
    - Euratom and radioprotection.
    - EU Beating Cancer plan.
    - EU Cancer Mission.
    - EU Roadmap for a pharmaceutical strategy for Europe.
    - Pharmaceutical strategy for Europe
    - EU pharmaceutical legislation
    - EU Partnership for Health Innovation.
    - European Health Data Space


    Head Office
    avenue Mounier, 83
    Brussels 1200
    EU Office
    avenue Mounier, 83
    Brussels 1200


  • People

    Total lobbyists declared


    Employment timeLobbyists

    Lobbyists (Full time equivalent)


    Lobbyists with EP accreditation

    No lobbyists with EP accreditations

    Complementary Information

    We are collaborating with VLASSEMBROUCK Consult/ABV Development for our interest representation activities (64547 euros in 2023)

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories


    Non-governmental organisations, platforms and networks and similar

  • Networking


    European Cancer Organisation
    European Forum for Good Clinical Practice
    European Alliance for Personnalised Medicine
    European Association for NeuroOncology
    European Association of Urology
    European School of Oncology
    European Association of Urology
    American Association for Cancer Research
    European Society for Therapeutic Radiology and Oncology
    European Society for Medical Oncology
    American Society for Therapeutic Radiology and Oncology
    International Society of Geriatric Oncology
    International Society of Pediatric Oncology
    International Union Against Cancer
    International Network for Cancer Research and Treatment
    Organisation of European Cancer Institutes
    European Oncology Nursing Society
    European Society of Pathology
    European Society of Radiology

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Does not represent commercial interests

    Closed financial year

    Jan 2022 - Dec 2022

    Lobbying costs for closed financial year

    Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.

    Total organisational budget in closed year


    Major funding types in closed year

    Grants, Other, Public funding

    Funding types "other" information

    EORTC raised 38.6 million euros incomes in 2022. 47% is coming from grants from the industry, 12% is coming from grants from non-commercial partners, 26% from from clinical research expert services and license for Quality of Life research tools, 7% from translation of Quality of Life questionnaires, 6% from subsidies, 2% from congresses/events

    Major contributions in closed year

    Contribution Bayer US 4,845,599€
    Contribution Merck Sharp & Dohme 4,148,874€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    None declared

    Groups (European Parliament)


    Communication activities

    Participation in workshops and conference involving EU institutions officials. Position statement in collaboration with stakeholders groups such European Cancer Organisation, European Alliance for Personalised Medicine, BioMedAlliance, Rare Cancers Europe, EFGCP, European Data in Health Research Alliance, European Federation of Pharmaceutical Industries, FIPRA.

    EORTC is represented in the following working groups: Commission Expert Group on Clinical Trials, Commission HTA stakeholders pool, EMA CTIS new delivery model, EMA EV- Expert Working Group, Accelerating clinical trials in the EU (ACT EU) initiative, .

    The EORTC is co-chairing the Cancer Medicines Forum together with the European Medicines Agency (EMA) which aims to advance treatment optimisation for approved cancer medicines. This includes by identifying and prioritizing research questions as well as policy issues emerging from the academic community

    Other activities

    None declared

  • Meetings


    8 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: All information below comes from European Commission web pages.

Download this datacard